These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19270204)

  • 21. Treatment of metabolic syndrome in peritoneal dialysis patients.
    Li PK; Kwan BC; Ko GT; Chow KM; Leung CB; Szeto CC
    Perit Dial Int; 2009 Feb; 29 Suppl 2():S149-52. PubMed ID: 19270205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk in peritoneal dialysis.
    Prichard S
    Contrib Nephrol; 2003; (140):82-90. PubMed ID: 12800347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A story half untold: adiposity, adipokines and outcomes in dialysis population.
    Kwan BC; Beddhu S
    Semin Dial; 2007; 20(6):493-7. PubMed ID: 17991193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose and Insulin Response to Peritoneal Dialysis Fluid in Diabetic and Nondiabetic Peritoneal Dialysis Patients.
    Oba I; Mori T; Chida M; Kurasawa N; Naganuma E; Sato E; Koizumi K; Sato S; Tsuchikawa M; Ito S
    Adv Perit Dial; 2015; 31():11-6. PubMed ID: 26714381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.
    Lambie M; Bonomini M; Davies SJ; Accili D; Arduini A; Zammit V
    Trends Endocrinol Metab; 2021 Sep; 32(9):721-730. PubMed ID: 34266706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients.
    Canbakan M; Sahin GM
    Ren Fail; 2007; 29(3):289-93. PubMed ID: 17497442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
    Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
    Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the Impact of Different Hypercaloric Diets on Weight Gain, Insulin Resistance, Glucose Intolerance, and its Comorbidities in Rats.
    Melo BF; Sacramento JF; Ribeiro MJ; Prego CS; Correia MC; Coelho JC; Cunha-Guimaraes JP; Rodrigues T; Martins IB; Guarino MP; Seiça RM; Matafome P; Conde SV
    Nutrients; 2019 May; 11(6):. PubMed ID: 31141900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation in peritoneal dialysis: a Latin-American perspective.
    Cueto-Manzano AM; González-Espinoza L; Martin del Campo F; Fortes PC; Pecoits-Filho R
    Perit Dial Int; 2007; 27(3):347-52. PubMed ID: 17468489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement and Correlation of Indices of Insulin Resistance in Patients on Peritoneal Dialysis.
    King-Morris KR; Deger SM; Hung AM; Egbert PA; Ellis CD; Graves A; Shintani A; Ikizler TA
    Perit Dial Int; 2016; 36(4):433-41. PubMed ID: 26526047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose challenge test (50-g GCT) in detection of glucose metabolism disorders in peritoneal dialysis patients: preliminary study.
    Madziarska K; Zmonarski S; Penar J; Krajewska M; Mazanowska O; Augustyniak-Bartosik H; Gołebiowski T; Klak R; Weyde W; Klinger M
    Int Urol Nephrol; 2015 Apr; 47(4):695-700. PubMed ID: 25539618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic consequences of hyperglycemia and insulin resistance.
    Jellinger PS
    Clin Cornerstone; 2007; 8 Suppl 7():S30-42. PubMed ID: 18154189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance and the metabolic syndrome.
    Lann D; Gallagher E; Leroith D
    Minerva Med; 2008 Jun; 99(3):253-62. PubMed ID: 18497723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between metabolic syndrome components and the development of atherosclerosis.
    Aboonabi A; Meyer RR; Singh I
    J Hum Hypertens; 2019 Dec; 33(12):844-855. PubMed ID: 31636352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum insulin and insulin-like growth factor binding protein-1 levels in adult patients undergoing peritoneal dialysis.
    Iglesias P; Grande C; Méndez J; Fernandez-Reyes MJ; Bajo MA; Selgas R; Díez JJ
    Adv Perit Dial; 1996; 12():71-6. PubMed ID: 8865877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic tools for dyslipidemia in peritoneal dialysis patients.
    Scarpioni R
    J Nephrol; 2009; 22(1):46-58. PubMed ID: 19229818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of renal osteodystrophy in peritoneal dialysis.
    Weinreich T
    Kidney Int; 1998 Dec; 54(6):2226-33. PubMed ID: 9853289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dyslipidemia and stroke in patients with chronic kidney disease].
    Kes P; Bašić-Kes V; Furic-Cunko V; Mesar I; Bašić-Jukić N
    Acta Med Croatica; 2014 Apr; 68(2):141-9. PubMed ID: 26012152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic kidney disease as a metabolic syndrome with malnutrition--need for strict control of risk factors.
    Shoji T; Nishizawa Y
    Intern Med; 2005 Mar; 44(3):179-87. PubMed ID: 15805704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal administration of insulin during peritoneal dialysis of diabetics with terminal renal failure.
    Anderson KE; Petersen PH
    Int J Artif Organs; 1981 Jul; 4(4):162-7. PubMed ID: 7035377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.